Abemaciclib plus Standard Adjuvant ET versus Standard Adjuvant ET Alone in High-Risk Breast Cancer

Conference Correspondent  - SABCS

 

Abemaciclib, an oral, selective inhibitor of CDK4/6 dosed on a twice-daily, continuous schedule, has demonstrated clinical efficacy and tolerability in patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer when administered as monotherapy (MONARCH 1) and in combination with endocrine therapy (ET) in MONARCH 2 and MONARCH 3.1-3 In neoMONARCH, abemaciclib plus anastrozole as neoadjuvant therapy reduced the breast tumor cell proliferation marker Ki67 to a greater extent than anastrozole alone after 2 weeks of treatment.4 Endocrine monotherapy is the current standard of care in the adjuvant setting. However, relapse occurs among a proportion of patients despite this therapy. A population with a higher risk for recurrence (15% at 5 years) may be identified based on the clinical and pathologic characteristics of disease. Thus, optimizing adjuvant therapy for these patients is an important clinical need.

MonarchE (NCT03155997) is a multicenter, randomized, open-label phase 3 trial that will evaluate the potential for abemaciclib to enhance adjuvant ET.5 Patients will be randomized 1:1 to an abemaciclib 150-mg twice-daily continuous schedule plus standard of care (SOC) adjuvant ET versus SOC adjuvant ET alone, and will be stratified by prior chemotherapy (neoadjuvant, adjuvant, or none), menopausal status (pre- or post-), and region (North America/Europe, Asia, or other). Patients may have started ET within 8 weeks prior to randomization, and will receive abemaciclib for up to 2 years in combination with ET (such as tamoxifen or an aromatase inhibitor, ± ovarian suppression, per physician’s choice). ET alone will be continued as clinically indicated. All randomized patients will be followed for a total of 10 years. Eligible patients (male or female) must have early-stage, resected HR-positive/HER2-negative, invasive breast cancer with either ≥4 positive pathologic axillary lymph nodes (pALNs), or 1 to 3 positive pALNs and ≥1 of the following high-risk markers: primary tumor size ≥5, histologic grade 3 tumor, or centrally assessed Ki67 index of ≥20% (in a subset of patients), and must have completed definitive locoregional therapy (± [neo]adjuvant chemotherapy) and be randomized ≤12 weeks after completion of last non-ET (surgery, chemotherapy, or radiotherapy). Patients must have tumor tissue available for biomarker analysis prior to randomization.

The primary objective of MonarchE is to evaluate invasive disease-free survival (IDFS) per the STEEP System.6 Secondary objectives include evaluation of IDFS in patients with Ki67 index ≥20%, distant relapse-free survival, overall survival, safety, pharmacokinetics, and patient health outcomes. Target accrual for the trial is approximately 3580 patients.

References

  1. Dickler MN, et al. Clin Cancer Res. 2017;23:5218-5224.
  2. Sledge GW Jr, et al. J Clin Oncol. 2017;35:2875-2884.
  3. Goetz MP, et al. J Clin Oncol. 2017;35:3638-3646.
  4. Hurvitz MM, et al. SABCS 2017. Abstract PD5-01.
  5. Rastogi P, et al. SABCS 2017. Abstract OT3-05-05.
  6. Hudis CA, et al. J Clin Oncol. 2007;25:2127-2132.
Related Items
Questions About Treating Patients Using a CDK4/6 Inhibitor
Matthew P. Goetz, MD
Conference Correspondent  published on December 10, 2017 in Breast Cancer, Video, SABCS
The Use of Chemotherapy in the Metastatic Setting
Matthew P. Goetz, MD
Conference Correspondent  published on December 10, 2017 in Breast Cancer, Video, SABCS
The Mechanism of Action of CDK4/6 Inhibitors
Matthew P. Goetz, MD
Conference Correspondent  published on December 10, 2017 in Breast Cancer, Video, SABCS
New Oral SERD Elacestrant Shows Efficacy in Breast Cancer Harboring ESR1 Mutations
Conference Correspondent  published on December 10, 2017 in SABCS
CDK6 Could Be a Key Factor for Efficacy of CDK4/6 Inhibitors and the Hormone Sensitivity Following Acquired Resistance
Conference Correspondent  published on December 10, 2017 in SABCS
Therapeutic Targeting of CDK4/6 Inhibitor–Resistant Breast Cancer
Conference Correspondent  published on December 10, 2017 in SABCS
Loss of Mismatch Repair Predicts Resistance to Endocrine Therapy and Sensitivity to CDK4/6 Inhibitors in ER-Positive Breast Cancer
Conference Correspondent  published on December 10, 2017 in SABCS
Xentuzumab and Abemaciclib plus Endocrine Therapy in Locally Advanced/Metastatic Breast Cancer
Conference Correspondent  published on December 10, 2017 in SABCS
CDK4/6 Inhibitors in HER2+ Metastatic Breast Cancer
Matthew P. Goetz, MD
Conference Correspondent  published on December 10, 2017 in Breast Cancer, Video, SABCS
CDK4/6 Inhibitors vs Chemotherapy for Patients with Metastatic Breast Cancer
Hope S. Rugo, MD
Conference Correspondent  published on December 9, 2017 in Breast Cancer, Video, SABCS
Last modified: April 27, 2020